Tirzepatide explained: the dual-agonist behind Mounjaro and Zepbound
Tirzepatide hits two gut hormone receptors instead of one. Here is what that actually means, and why the SURMOUNT trial data made it the headline story of the GLP-1 era.
Key points
- Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin hormones, not just one.
- SURMOUNT-1 showed average weight reduction of ~20% at the highest dose over 72 weeks.
- Sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).
- Side effect profile is similar to semaglutide — GI symptoms that taper with titration.
Why two receptors instead of one matters
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide activates GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP appears to complement GLP-1 by improving insulin sensitivity and, in combination, producing stronger appetite and weight effects than either signal alone.
In practice, patients often describe the appetite suppression as noticeable sooner and a bit more complete than what they experienced on semaglutide.
What the trials actually showed
In SURMOUNT-1, adults without diabetes on tirzepatide 15 mg lost an average of ~20.9% of body weight over 72 weeks compared to ~3.1% on placebo. SURMOUNT-2, in adults with type 2 diabetes, showed ~14-15% reductions — still well above typical semaglutide results in comparable populations.
Head-to-head data (SURPASS-2) in type 2 diabetes favored tirzepatide over semaglutide on both A1c and weight endpoints.
Who it is for, and caveats
Eligibility criteria mirror semaglutide — adults with obesity or overweight with a weight-related condition. The contraindications (MTC, MEN2 history, pancreatitis) are the same class warnings.
The honest trade-off: tirzepatide is newer, supply has been tighter at times, and cost can be higher depending on insurance. For many patients the stronger effect is worth navigating those frictions.